B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104

Benzinga Newsdesk www.benzinga.com Positive 85.2%

Neg 0% Neu 0% Pos 85.2%

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $101 to $104.